Cambridge, UK – In a landmark development that could fundamentally alter the treatment landscape for patients with aggressive, inherited breast cancers, researchers at Cambridge have unveiled a novel therapeutic approach demonstrating an unprecedented 100% survival rate three years post-surgery. This pioneering strategy, detailed in a study published today in Nature Communications, combines conventional chemotherapy with a targeted cancer drug, olaparib, administered pre-surgically with a precisely timed interval.
The findings, emanating from the "Partner" trial led by Addenbrooke’s Hospital, part of Cambridge University Hospitals (CUH) NHS Foundation Trust and the University of Cambridge, represent a significant leap forward in tackling cancers driven by faulty copies of the BRCA1 and BRCA2 genes. These specific mutations are notoriously challenging to treat and carry a heightened risk of recurrence.
Professor Jean Abraham, a consultant at Addenbrooke’s and the trial lead, expressed profound enthusiasm for the results. "It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer," she stated. "We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers."
The Partner Trial: A Paradigm Shift in Pre-Surgical Strategy
The Partner trial introduced two critical innovations that distinguish it from standard care. Firstly, it integrated olaparib, a targeted cancer drug already available on the NHS and taken as tablets, into the pre-surgical treatment regimen. Secondly, and perhaps most ingeniously, it established the benefits of careful timing, specifically a 48-hour "gap" between the administration of chemotherapy and olaparib. This strategic pause, researchers believe, allows a patient’s bone marrow to recover from the cytotoxic effects of chemotherapy, while simultaneously leaving the tumour cells uniquely susceptible to the targeted action of olaparib.
Unprecedented Survival Rates Unveiled
The trial enrolled patients from 23 NHS sites across the UK. Of the 39 patients who received the innovative chemotherapy-followed-by-olaparib protocol, a remarkable 100% survived the critical three-year period following surgery. Only one patient in this cohort experienced a relapse.
This outcome stands in stark contrast to the control arm of the study, which comprised 45 patients who received chemotherapy only. In the control group, the survival rate three years after surgery was 88%. A troubling nine patients relapsed, six of whom tragically succumbed to their disease. The difference in outcomes underscores the profound impact of the new treatment approach, offering a tangible beacon of hope for patients facing these aggressive diagnoses.
The Ingenuity of Timed Therapy: A 48-Hour ‘Gap’
The concept of the 48-hour gap emerged from a "chance conversation" between Professor Abraham and Mark O’Connor, chief scientist in Early Oncology R&D at AstraZeneca. This serendipitous discussion ignited a scientific inquiry into how best to sequence these powerful drugs to maximise efficacy and minimise harm.
The prevailing hypothesis is that chemotherapy, while killing cancer cells, also impacts rapidly dividing healthy cells, including those in the bone marrow responsible for producing blood cells. By allowing a brief recovery period, the bone marrow can regain some strength. Simultaneously, the damaged tumour cells, weakened by chemotherapy, become more vulnerable to olaparib. Olaparib is a PARP inhibitor, a class of drugs that exploits deficiencies in DNA repair pathways, which are often inherent in BRCA-mutated cancers. The timing ensures that the cancer cells are at their most fragile state when olaparib is introduced, delivering a more potent and precise strike.
Understanding the Enemy: The Challenge of BRCA1 and BRCA2 Mutations
Breast cancers linked to faulty copies of the BRCA1 and BRCA2 genes are among the most aggressive forms of the disease. These genes play a crucial role in repairing damaged DNA, acting as guardians of our genetic code. When they are mutated, this repair mechanism is compromised, leading to an increased risk of various cancers, most notably breast and ovarian cancers.
The Genetic Link and Public Awareness
The inherited nature of these mutations gained significant public attention in 2013 when actress Angelina Jolie, a carrier of a BRCA1 mutation, underwent a preventative double mastectomy. Her candid decision brought global awareness to the genetic predisposition for certain cancers and the difficult choices individuals face. While her action highlighted preventative measures, the Partner trial focuses on those already diagnosed, offering a much-needed improvement in active treatment strategies. The challenge for clinicians has always been the inherent aggressiveness of these tumour types, which often present at a younger age and are more prone to rapid growth and metastasis.
Current Landscape of Treatment
Standard treatment for early-stage breast cancer with BRCA mutations typically involves a combination of chemotherapy and sometimes immunotherapy, aimed at shrinking the tumour (neoadjuvant therapy) before surgical removal. The goal is to reduce tumour size, making surgery more effective and potentially allowing for less invasive procedures. However, even with these treatments, the first three years after surgery remain a critical period, marked by the highest risk of relapse or death. It is precisely this window of vulnerability that the Partner trial sought to address, and its results suggest a powerful new means of extending survival and improving prognosis.
The Journey to Discovery: From Chance Conversation to Clinical Trial
The genesis of the Partner trial underscores the often-unpredictable path of scientific discovery, where informal dialogue can spark revolutionary ideas. Professor Abraham’s conversation with Mark O’Connor highlighted a shared interest in optimising drug delivery and understanding cellular responses.
The Scientific Rationale Behind the ‘Gap’
The scientific basis for the 48-hour gap is rooted in cellular kinetics and pharmacology. Chemotherapy agents indiscriminately target rapidly dividing cells. While effective against cancer, this broad action also affects healthy cells, including the hematopoietic stem cells in the bone marrow that produce blood components. A brief respite allows these healthy cells to recover, thereby mitigating some of chemotherapy’s severe side effects, such as myelosuppression (reduced bone marrow activity).
Concurrently, the chemotherapy-induced damage to tumour cells, particularly their DNA, primes them for the subsequent action of olaparib. Olaparib, as a PARP inhibitor, works by preventing cancer cells from repairing their DNA. In BRCA-mutated cells, which already have impaired DNA repair pathways, inhibiting PARP creates a ‘synthetic lethality’ – a condition where the combination of two non-lethal events becomes lethal. The timing ensures that olaparib hits the cancer cells when their DNA repair mechanisms are already maximally stressed and their ability to cope is at its lowest.
A Collaborative Effort Across the UK
The Partner trial was not confined to a single institution but was a testament to collaborative clinical research across the UK. With patients recruited from 23 NHS sites, it demonstrated the capacity of the national health service to mobilise resources for cutting-edge trials. This broad recruitment base ensures that the findings are robust and potentially applicable to a diverse patient population within the UK, laying the groundwork for wider adoption if future studies confirm these results. The trial was sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, funded by Cancer Research UK and AstraZeneca, and supported by a consortium of research bodies, highlighting the power of multi-institutional and multi-funder collaboration.
A Patient’s Story: Hope Rekindled for Jackie Van Bochoven
Behind the statistics and scientific breakthroughs are the individual lives transformed by these advances. Jackie Van Bochoven, 59, from South Cambridgeshire, embodies the hope offered by the Partner trial’s success. Diagnosed in February 2019 with a small but aggressive tumour, Jackie’s initial reaction was one of profound shock and fear.
"When I had the diagnosis, I was completely shocked and numb, I thought about my children, and my mum and sister who were diagnosed with breast cancer," Jackie recounted, reflecting on the weight of her family history and the immediate anxieties for her loved ones. "I was pretty worried." The specter of a disease that had already touched her family amplified her distress, making her diagnosis all the more terrifying.
However, Jackie’s journey since her diagnosis has been one of remarkable recovery and renewed perspective. "Six years on, I’m well and cancer free," she shared with palpable relief and gratitude. "I’m back at work, enjoying life and spending time with my family. When you’ve had cancer, I think you look at life differently and every day is a bonus." Her story is a powerful testament to the tangible impact of effective treatment, turning initial despair into a profound appreciation for life and health. Her experience underscores the ultimate goal of cancer research: not just to extend life, but to restore its quality and allow patients to return to their families and passions.
Expert Voices on a Groundbreaking Advance
The scientific community and cancer charities have lauded the results of the Partner trial, recognising its potential to usher in a new era of personalised and effective treatment for a particularly vulnerable patient group.
Professor Jean Abraham: "Incredibly Excited" by Rare Survival Rates
Professor Jean Abraham, who also holds the title of Professor of Precision Breast Cancer Medicine at the University of Cambridge, reiterated the exceptional nature of achieving a 100% survival rate in such an aggressive cancer cohort. Her vision extends beyond the immediate findings, aiming to solidify this approach as a definitive cure for BRCA1 and BRCA2 related cancers. She emphasised the critical need to continually innovate in the face of these formidable diseases. Her leadership, from the initial "chance conversation" to the successful execution of the trial, highlights the crucial role of dedicated clinical researchers in translating scientific ideas into patient benefit.
Mark O’Connor: Highlighting Innovative Science and Unmet Needs
Mark O’Connor of AstraZeneca underscored the broader implications of the trial’s design and findings. "The Partner trial highlights the importance of detecting and treating cancer early, and the value of innovative science in informing clinical trial design, in this case using bone marrow stem cells to identify the combination gap schedule," he noted. His comments point to the intelligent integration of basic biological understanding (bone marrow recovery) with clinical strategy. He also stressed that while the findings are "incredibly exciting," they "need to be validated in a larger study," a standard and necessary step in medical research before widespread clinical adoption. However, he remains optimistic about the potential to "transform outcomes for patient populations who have unmet clinical need."
Michelle Mitchell: Optimising Existing Treatments for Greater Impact
Michelle Mitchell, Chief Executive of Cancer Research UK, echoed the sentiment of leveraging existing resources more effectively. "One of the best ways that we can beat cancer sooner is by making more effective use of treatments that are already available to us," she said. This perspective is particularly relevant given that olaparib is already an approved drug, making its re-purposing and optimisation a more rapid path to patient benefit than developing entirely new compounds. She further highlighted the emotional impact of the findings: "While this research is still in its infancy, it is an exciting discovery that adding olaparib at a carefully-timed stage of treatment can potentially give patients with this specific type of breast cancer more time with their loved ones." Mitchell also prudently called for "further studies in more patients to confirm whether this new technique is safe and effective enough to be used by the NHS."
Far-Reaching Implications: Beyond Breast Cancer and Towards a New Era of Care
The success of the Partner trial extends far beyond the immediate cohort of breast cancer patients, promising a cascade of benefits across oncology.
Potential for Other BRCA-Related Cancers
A particularly exciting implication is the potential applicability of this treatment approach to other cancers caused by faulty copies of BRCA genes. This includes certain ovarian, prostate, and pancreatic cancers. Given that the underlying genetic defect and subsequent DNA repair deficiencies are common across these tumour types, a similar targeted approach, exploiting the ‘synthetic lethality’ principle, could prove equally effective. This opens doors for new clinical trials in these challenging cancer types, potentially offering a lifeline to patients with limited treatment options.
Economic Benefits and Patient Quality of Life
Beyond the profound clinical benefits, the Partner trial also hints at significant cost-saving advantages for the NHS. Currently, patients offered olaparib typically take the drug post-surgery for 12 months. In contrast, patients on the trial took the tablets pre-surgery for only 12 weeks. This substantial reduction in treatment duration for olaparib could lead to considerable cost savings for healthcare systems, freeing up resources for other critical patient needs. Furthermore, a shorter course of treatment could mean fewer side effects for patients, improved quality of life during treatment, and potentially better adherence, all contributing to a more patient-centric care model.
The Future: Larger Trials and Collaborative Innovation
Professor Abraham and her team are now meticulously planning the next phase of research. This crucial step will involve a larger-scale study designed to replicate the impressive results of the Partner trial. The aim is not only to confirm the high survival rates in a broader population but also to rigorously demonstrate that the Partner approach offers a less toxic and more cost-effective treatment compared to the current standard of care. This commitment to thorough validation is essential for gaining widespread acceptance and integration into routine clinical practice.
The Cambridge Model: A Blueprint for Cancer Research
The Partner trial stands as a powerful exemplar of the collaborative vision championed by the Cambridge Cancer Research Hospital. This specialist cancer research hospital, soon to be built on Europe’s leading life sciences campus, the Cambridge Biomedical Campus, aims to unite clinical expertise from Addenbrooke’s Hospital with world-class scientists from the University of Cambridge, the Cancer Research UK Cambridge Centre, and industry partners. By bringing these diverse stakeholders together in one location, the hospital seeks to accelerate the creation of new diagnostics and treatments, enabling earlier detection of cancer and the delivery of highly personalised, precision medicine. The success of the Partner trial, forged through precisely this kind of multidisciplinary partnership, serves as a compelling proof-of-concept for this ambitious model.
In conclusion, the Cambridge-led Partner trial offers a transformative glimmer of hope for patients battling aggressive, inherited breast cancers. By ingeniously combining existing therapies with precise timing, researchers have unlocked a new pathway to significantly improved survival. While further studies are rightly warranted, the initial results herald a potential paradigm shift, promising a future where a diagnosis of BRCA-related cancer no longer carries the same grim prognosis, and where innovation, collaboration, and patient-centric care lead to longer, healthier lives.
About the Author
